The Role of Autoimmunity and Obesity in Polycystic Ovary Syndrome

Sponsor

Sohag University (Other)

Overall Status

Not yet recruiting

CT.gov ID

NCT05929950

Collaborator

(none)

Enrollment

Location

Anticipated Duration (Months)

Patients Per Site Per Month

Study Details

Study Description

Brief Summary

The goal of the study is to detect autoantibodies in the serum of the women with PCOS and evaluate the obesity markers to investigate the the role of autoimmunity and obesity in PCOS

Condition or Disease	Intervention/Treatment	Phase
Polycystic Ovary Syndrome

Study Design

Study Type:

Observational

Anticipated Enrollment :

90 participants

Observational Model:

Case-Control

Time Perspective:

Prospective

Official Title:

The Role of Autoimmunity and Obesity in Polycystic Ovary Syndrome

Anticipated Study Start Date :

Aug 1, 2023

Anticipated Primary Completion Date :

Mar 1, 2024

Anticipated Study Completion Date :

Jun 1, 2024

Arms and Interventions

Arm	Intervention/Treatment
patients with PCOS
control group

Outcome Measures

Primary Outcome Measures

measuring serum anti-ovarian, anti-nuclear, anti-double stranded and anti-thyroid antibodies [3 months after recruitment]
Theses markers will be measured using ELISA technique

Eligibility Criteria

Criteria

Ages Eligible for Study:

12 Years to 55 Years

Sexes Eligible for Study:

Female

Accepts Healthy Volunteers:

Yes

Inclusion Criteria:

patients diagnosed with PCOS according to the Rotterdam (2003) criteria.

Exclusion Criteria:

Patients with other causes of hyperandrogenism as congenital adrenal hyperplasia, androgen-secreting tumors, Cushing's syndrome, hyperprolactinemia, virilizing ovarian or adrenal tumors and those taking drugs affecting insulin resistance, such as estrogens, oral contraceptives and corticosteroids during the previous three months before the study.